Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ: ANNX )

5.230 +0.010 (+0.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,535,520
Open 5.090
Bid (Size) 5.000 (2)
Ask (Size) 5.210 (1)
Prev. Close 5.220
Today's Range 5.050 - 5.315
52wk Range 3.655 - 8.400
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
+8.06%
+8.06%
1 Month
+1.16%
+1.16%
3 Month
-21.35%
-21.35%
6 Month
+9.64%
+9.64%
1 Year
+30.42%
+30.42%

More News

Read More
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
ANNX Stock Earnings: Annexon Meets EPS for Q2 2024
Via InvestorPlace
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
From Annexon Biosciences
Via GlobeNewswire
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
From Annexon Biosciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
7 Top Stocks Under $10: June 2024 Edition
Via InvestorPlace
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.